Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congress
Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking place from September 9-12, 2021 and the presentations are as follows:
Prize Papers 7: Vascular Diseases & Diabetic Retinopathy II – THR-149
September 10 at 10:00 CEST
10:29 – Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis in a diabetic rat model
Presented by Tine Van Bergen, PhD, Oxurion NV, Belgium
10:33 – A Novel Bicyclic Peptide Inhibitor of Plasma Kallikrein, THR-149, for the Treatment of Diabetic Macular Edema (DME): Clinical and Pre-Clinical Evidence
Presented by Professor Francesco Bandello, M.D., Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan, Italy
Follow link for access to full program overview: Prize Papers 7: Vascular Diseases & Diabetic Retinopathy II – EURETINA
Euretina 2021 e-Poster presentation – THR-687
A Phase 1 Study of THR-687, an RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) in Patients Previously Responsive to anti-VEGF Agents or Corticosteroids
Presented by Raj K. Maturi, M.D., Midwest Eye Institute, Indianapolis, IN, USA
Follow link for access to abstract (p 217) and full overview of Euretina 2021 e-posters:
EURETINA-2021-Virtual-Abstract-Posters-2.pdf (d2jcwvonf1bqhq.cloudfront.net)